The 5th Gene Therapy for Neurological Disorders Europe is dedicated to the development and delivery of neurological gene therapies.
Topics
- Safety and toxicity strategies to navigate off target effects including redosing options
- The biology behind AAV toxicity in the CNS
- Vector discovery strategies used to identify vectors with improved CNS tropism and specificity
- Delivery devices to identify novel innovations and areas for development
- Indications being targeted by gene therapies such as neuropathic pain, epilepsy and hearing disorders
Who should Attend
Preclinical, discovery, translational and clinical industry scientists.
